Organizations Filed Purposes:
THE TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. WAS ORGANIZED AND IS OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, CONTROLLED BY LEADING NOT-FOR-PROFIT ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS, TO FURTHER AND IMPROVE HEALTH AND THE DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASE THROUGH FUTHERING AND IMPROVING TRANSLATIONAL RESEARCH, GENERATE INNOVATIVE PROOF-OF-CONCEPT STUDIES, AND ADVANCE THE SCIENTIFIC ACTIVITIES OF THE CONTROLLING INSTITUTIONS' (MEMORIAL SLOAN KETTERING CANCER CENTER, THE ROCKEFELLER UNIVERSITY AND WEIL CORNELL MEDICAL COLLEGE)FACULTY, FELLOWS AND STUDENTS IN ASPECTS OF TRANSLATIONAL RESEARCH, CHEMISTRY, PHARMACOLOGY, AND DRUG DISCOVERY.
THE TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, A PARTNERSHIP AMONG THREE WORLD-RENOWNED SCIENTIFIC AND MEDICAL INSTITUTIONS, WORKS TO MORE EFFECTIVELY DEVELOP THERAPEUTICS THAT ARISE FROM DISCOVERIES MADE IN BASIC SCIENCE LABS. WITH A FOCUS ON EARLY-STAGE DRUG DISCOVERY, THE INSTITUTE PROVIDES EXPERTISE IN MEDICINAL CHEMISTRY AND COMPOUND SCREENING, AND CONDUCTS PROOF OF CONCEPT STUDIES NEEDED TO DEMONSTRATE THAT DRUG CANDIDATES CAN SUCCESSFULLY ALTER THE COURSE OF A DISEASE. SPECIFIC RESEARCH PROJECTS FOCUS ON ALZHEIMERS DISEASE, SICKLE CELL, OSTEOPOROSIS, LYSOSOMAL, LIPID DEPOSITS, PARKINSON'S AND BASAL CELL CARCINOMA.
THE INSTITUTE FACILITATES MORE EFFICIENT SHARING OF CORE FACILITIES BETWEEN THE THREE PARTNER INSTITUTIONS AND FORMS INDUSTRY PARTNERSHIPS WITH PHARMACEUTICAL AND BIOTECH COMPANIES TO FURTHER ADVANCE DRUG RESEARCH. IT SEEKS TO CREATE INTELLECTUAL PROPERTY THAT CAN BE FURTHER DEVELOPED BY AN OPEN FIELD OF INDUSTRY COLLABORATORS. THE MAJORITY OF SUCH SERVICES RELATE TO MEDICINAL CHEMISTRY SUPPORT.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Peter T Meinke Phd | DIRECTOR | 40 | $545,468 |
| Ivo Lorenz Phd | VICE PRESIDENT, BIOLOGICS | 40 | $313,318 |
| Nigel Livertonphd | VICE PRESIDENT, CHEMISTRY | 40 | $241,145 |
| Paul Balderes Phd | DIRECTOR | 40 | $236,662 |
| Sandra Lorber | VICE PRESIDENT, FINANCE | 40 | $200,945 |
| Michael Miller Phd | DIRECTOR | 40 | $188,555 |
| David Andrew Phd | DIRECTOR | 40 | $184,294 |
| James H Lapple | TREASURER | 0 | $0 |
| Craig B Thompson Md | MEMBER OF THE BOARD OF DIR | 0 | $0 |
| David Scheinberg Md Phd | MEMBER OF THE BOARD OF DIR | 0 | $0 |
| Carl Nathan Md | MEMBER OF THE BOARD OF DIR | 0 | $0 |
| Richard P Lifton Mdphd | MEMBER OF THE BOARD OF DIR | 0 | $0 |
| Barry Coller Md | MEMBER OF THE BOARD OF DIR | 0 | $0 |
| Augustine Mk Choi Md | MEMBER OF THE BOARD OF DIR | 0 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202003109349300240_public.xml